1. Home
  2. VLYPO vs CMMB Comparison

VLYPO vs CMMB Comparison

Compare VLYPO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

VLYPO

Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

HOLD

Current Price

$25.18

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.85

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLYPO
CMMB
Founded
N/A
2004
Country
United States
Israel
Employees
3732
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
13.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VLYPO
CMMB
Price
$25.18
$1.85
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
N/A
95.6K
Earning Date
N/A
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.73
52 Week High
N/A
$9.84

Technical Indicators

Market Signals
Indicator
VLYPO
CMMB
Relative Strength Index (RSI) 49.07 28.56
Support Level $24.96 $2.01
Resistance Level $25.59 $2.21
Average True Range (ATR) 0.17 0.25
MACD -0.03 -0.05
Stochastic Oscillator 40.71 17.31

Price Performance

Historical Comparison
VLYPO
CMMB

About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: